Key result
Macrophage-targeted Ric-8B-Galpha interference peptide reduces atherosclerosis in preclinical models.
Why the study?
Macrophage stimulatory G-protein-cAMP signaling promotes cholesterol accumulation and inflammasome activation in atherosclerosis, but how obesity-associated inflammation amplifies this pathway was unknown.
Does disrupting the macrophage Ric-8B-Galpha interface reduce Galpha s/olf-cAMP signaling, inflammasome activation, and atherosclerosis in preclinical models?
Does disrupting the macrophage Ric-8B-Galpha interface reduce Galpha s/olf-cAMP signaling, inflammasome activation, and atherosclerosis in preclinical models?
Answers are grounded in this paper and cite their sources.
Identifies the macrophage Ric-8B-Galpha interface and obesity-associated IFN-gamma-ERK2-CK2alpha-Ric-8B signaling as key drivers of atherogenesis and a potential therapeutic target for atherosclerosis.
BACKGROUND: Macrophage stimulatory G-protein (Gα s/olf )-cAMP signaling promotes cholesterol accumulation and inflammasome activation in atherosclerosis. How obesity-associated inflammation amplifies this pathway is unknown. METHODS: We studied human and murine macrophages, genetically modified low-density lipoprotein receptor–deficient ( Ldlr –/– ) bone marrow chimeras, and human carotid plaques using biochemical assays and a macrophage-targeted resistance to inhibitors of cholinesterase 8B (Ric-8B)-Gα interference peptide. RESULTS: oxLDL (oxidized low-density lipoprotein) activated Gα olf through OR6A2 (olfactory receptor 6A2) and Gα s through downregulation of phosphorylated Gα-interacting vesicle-associated protein (p-GIV [phosphorylated Gα-interacting vesicle-associated protein]); both required Ric-8B. Ric-8B bound nucleotide-free Gα olf and Gα s with high affinity (K D , 21 and 29 nmol/L) through Arg75 and promoted their folding, stability, membrane localization, and cAMP signaling. Disrupting this interface reduced macrophage inflammasome activation and cholesterol accumulation. In Ldlr –/– chimeras, the targeted interference peptide localized to plaque macrophages, suppressed lesional Gα s/olf activity, and reduced atherosclerosis; these effects were absent with a nonbinding control peptide or Ric-8B R75E . In male patients’ carotid plaques, plasma IFN-γ (interferon-γ) correlated with macrophage-associated Ric-8B S468/T473 phosphorylation. IFN-γ activated a STAT1 (signal transducer and activator of transcription 1)-independent ERK2 (extracellular signal-regulated kinase 2)-casein kinase 2 α catalytic subunit pathway that phosphorylated Ric-8B at S468/T473, enhancing chaperone activity. Phosphomimetic substitution lowered the pooled fitted oxLDL EC 50 for cAMP generation (11.5 versus 27.7 µg/mL in wild-type cells) without increasing basal cAMP; replicate-level EC 50 estimates did not differ significantly ( P =0.17). This substitution restored the atherogenic phenotype suppressed by Ifngr1 deficiency in obese, but not nonobese, chimeras. CONCLUSIONS: Ric-8B sustains macrophage Gα s/olf –cAMP signaling and atherogenesis. Obesity-associated IFN-γ enhances macrophage responses to oxLDL through STAT1-independent ERK2–casein kinase 2 α catalytic subunit-Ric-8B signaling, supporting a 2-hit mechanism and identifying the Ric-8B-Gα interface as a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
胡子成 et al. (2026) studied Atherosclerosis. Macrophage-targeted Ric-8B-Galpha interference peptide and Ric-8B S468/T473 phosphomimetic substitution vs. Nonbinding control peptide, Ric-8B R75E mutant, or wild-type cells was evaluated on Pooled fitted oxLDL EC50 for cAMP generation and atherosclerosis progression (p=0.17). Macrophage-targeted Ric-8B-Galpha interference peptide reduced atherosclerosis in Ldlr-/- chimeras, while Ric-8B phosphomimetic substitution lowered the pooled fitted oxLDL EC50 for cAMP.
Synapse has enriched 10 related papers. Consider them for comparative context: